Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era (Leukemia, (2020), 34, 12, (3338-3347), 10.1038/s41375-020-0830-0)

Binod Dhakal; Sagar Patel; Saulius Girnius; Lohith Bachegowda; Raphael Fraser; Omar Davila; Abraham S. Kanate; Amer Assal; Amr Hanbali; Asad Bashey; Attaphol Pawarode; César O. Freytes; Cindy Lee; David Vesole; Robert Frank Cornell; Gerhard C. Hildebrandt; Hemant S. Murthy; Hillard M. Lazarus; Jan Cerny; Jean A. Yared; Jeffrey Schriber; Jesus Berdeja; Keith Stockerl-Goldstein; Kenneth Meehan; Leona Holmberg; Melhem Solh; Miguel Angel Diaz; Mohamed A. Kharfan-Dabaja; Nosha Farhadfar; Qaiser Bashir; Reinhold Munker; Richard F. Olsson; Robert P. Gale; Ruthlee Lu Bayer; Sachiko Seo; Saurabh Chhabra; Shahrukh Hashmi; Sherif M. Badawy; Taiga Nishihori; Wilson Gonsalves; Yago Nieto; Yvonne Efebera; Shaji Kumar; Nina Shah; Muzaffar Qazilbash; Parameswaran Hari; Anita D’Souza

doi:10.1038/s41375-021-01233-1

Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era (Leukemia, (2020), 34, 12, (3338-3347), 10.1038/s41375-020-0830-0)

Binod Dhakal, Sagar Patel, Saulius Girnius, Lohith Bachegowda, Raphael Fraser, Omar Davila, Abraham S. Kanate, Amer Assal, Amr Hanbali, Asad Bashey, Attaphol Pawarode, César O. Freytes, Cindy Lee, David Vesole, Robert Frank Cornell, Gerhard C. Hildebrandt, Hemant S. Murthy, Hillard M. Lazarus, Jan Cerny, Jean A. YaredJeffrey Schriber, Jesus Berdeja, Keith Stockerl-Goldstein, Kenneth Meehan, Leona Holmberg, Melhem Solh, Miguel Angel Diaz, Mohamed A. Kharfan-Dabaja, Nosha Farhadfar, Qaiser Bashir, Reinhold Munker, Richard F. Olsson, Robert P. Gale, Ruthlee Lu Bayer, Sachiko Seo, Saurabh Chhabra, Shahrukh Hashmi, Sherif M. Badawy, Taiga Nishihori, Wilson Gonsalves, Yago Nieto, Yvonne Efebera, Shaji Kumar, Nina Shah, Muzaffar Qazilbash, Parameswaran Hari, Anita D’Souza

Stem Cell Transplantation

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The acknowledgement of the original article was incomplete. Correct is should read: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); U24HL138660 from NHLBI and NCI; U24CA233032 from the NCI; OT3HL147741, and U01HL128568 from the NHLBI; HHSH250201700006C, and HHSH250201700007C from the Health Resources and Services Administration (HRSA); and N00014-20-1- 2705 and N00014-20-1-2832 from the Office of Naval Research; Additional federal support is provided by P01CA111412, R01CA152108, R01CA215134, R01C A218285, R01CA231141, R01AI128775, R01HL126589, R01HL129472, R01HL130388, R01HL131731, U01AI 069197, U01AI126612, UG1HL06924, and BARDA. Support is also provided by Be the Match Foundation, Boston Children’s Hospital, Dana Farber, St. Baldrick’s Foundation, Stanford University, the Medical College of Wisconsin the National Marrow Donor Program, and from the following commercial entities: Actinium Pharmaceuticals, Inc.; Adienne SA; Allovir, Inc.; Amgen, Inc.; Angiocrine Bioscience; Astellas Pharma US; bluebird bio, Inc.; Bristol Myers Squibb Co.; Celgene Corp.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd.; Genentech Inc; Incyte Corporation; Janssen/Johnson & Johnson; Jazz Pharmaceuticals, Inc.; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Merck Sharp & Dohme Corp.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Stemcyte; Takeda Pharma; Vor Biopharma; Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. The original article has been corrected.

Original language	English (US)
Pages (from-to)	1828
Number of pages	1
Journal	Leukemia
Volume	35
Issue number	6
DOIs	https://doi.org/10.1038/s41375-021-01233-1
State	Published - Jun 2021

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-021-01233-1

Cite this

Dhakal, B., Patel, S., Girnius, S., Bachegowda, L., Fraser, R., Davila, O., Kanate, A. S., Assal, A., Hanbali, A., Bashey, A., Pawarode, A., Freytes, C. O., Lee, C., Vesole, D., Cornell, R. F., Hildebrandt, G. C., Murthy, H. S., Lazarus, H. M., Cerny, J., ... D’Souza, A. (2021). Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era (Leukemia, (2020), 34, 12, (3338-3347), 10.1038/s41375-020-0830-0). Leukemia, 35(6), 1828. https://doi.org/10.1038/s41375-021-01233-1

Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era (Leukemia, (2020), 34, 12, (3338-3347), 10.1038/s41375-020-0830-0). / Dhakal, Binod; Patel, Sagar; Girnius, Saulius et al.
In: Leukemia, Vol. 35, No. 6, 06.2021, p. 1828.

Research output: Contribution to journal › Comment/debate › peer-review

Dhakal, B, Patel, S, Girnius, S, Bachegowda, L, Fraser, R, Davila, O, Kanate, AS, Assal, A, Hanbali, A, Bashey, A, Pawarode, A, Freytes, CO, Lee, C, Vesole, D, Cornell, RF, Hildebrandt, GC, Murthy, HS, Lazarus, HM, Cerny, J, Yared, JA, Schriber, J, Berdeja, J, Stockerl-Goldstein, K, Meehan, K, Holmberg, L, Solh, M, Diaz, MA, Kharfan-Dabaja, MA, Farhadfar, N, Bashir, Q, Munker, R, Olsson, RF, Gale, RP, Bayer, RL, Seo, S, Chhabra, S, Hashmi, S, Badawy, SM, Nishihori, T, Gonsalves, W, Nieto, Y, Efebera, Y, Kumar, S, Shah, N, Qazilbash, M, Hari, P & D’Souza, A 2021, 'Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era (Leukemia, (2020), 34, 12, (3338-3347), 10.1038/s41375-020-0830-0)', Leukemia, vol. 35, no. 6, pp. 1828. https://doi.org/10.1038/s41375-021-01233-1

@article{886186fbcc1f499d99b85fcc3ef1cf90,

title = "Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era (Leukemia, (2020), 34, 12, (3338-3347), 10.1038/s41375-020-0830-0)",

abstract = "The acknowledgement of the original article was incomplete. Correct is should read: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); U24HL138660 from NHLBI and NCI; U24CA233032 from the NCI; OT3HL147741, and U01HL128568 from the NHLBI; HHSH250201700006C, and HHSH250201700007C from the Health Resources and Services Administration (HRSA); and N00014-20-1- 2705 and N00014-20-1-2832 from the Office of Naval Research; Additional federal support is provided by P01CA111412, R01CA152108, R01CA215134, R01C A218285, R01CA231141, R01AI128775, R01HL126589, R01HL129472, R01HL130388, R01HL131731, U01AI 069197, U01AI126612, UG1HL06924, and BARDA. Support is also provided by Be the Match Foundation, Boston Children{\textquoteright}s Hospital, Dana Farber, St. Baldrick{\textquoteright}s Foundation, Stanford University, the Medical College of Wisconsin the National Marrow Donor Program, and from the following commercial entities: Actinium Pharmaceuticals, Inc.; Adienne SA; Allovir, Inc.; Amgen, Inc.; Angiocrine Bioscience; Astellas Pharma US; bluebird bio, Inc.; Bristol Myers Squibb Co.; Celgene Corp.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd.; Genentech Inc; Incyte Corporation; Janssen/Johnson & Johnson; Jazz Pharmaceuticals, Inc.; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Merck Sharp & Dohme Corp.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Stemcyte; Takeda Pharma; Vor Biopharma; Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. The original article has been corrected.",

author = "Binod Dhakal and Sagar Patel and Saulius Girnius and Lohith Bachegowda and Raphael Fraser and Omar Davila and Kanate, {Abraham S.} and Amer Assal and Amr Hanbali and Asad Bashey and Attaphol Pawarode and Freytes, {C{\'e}sar O.} and Cindy Lee and David Vesole and Cornell, {Robert Frank} and Hildebrandt, {Gerhard C.} and Murthy, {Hemant S.} and Lazarus, {Hillard M.} and Jan Cerny and Yared, {Jean A.} and Jeffrey Schriber and Jesus Berdeja and Keith Stockerl-Goldstein and Kenneth Meehan and Leona Holmberg and Melhem Solh and Diaz, {Miguel Angel} and Kharfan-Dabaja, {Mohamed A.} and Nosha Farhadfar and Qaiser Bashir and Reinhold Munker and Olsson, {Richard F.} and Gale, {Robert P.} and Bayer, {Ruthlee Lu} and Sachiko Seo and Saurabh Chhabra and Shahrukh Hashmi and Badawy, {Sherif M.} and Taiga Nishihori and Wilson Gonsalves and Yago Nieto and Yvonne Efebera and Shaji Kumar and Nina Shah and Muzaffar Qazilbash and Parameswaran Hari and Anita D{\textquoteright}Souza",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2021",

month = jun,

doi = "10.1038/s41375-021-01233-1",

language = "English (US)",

volume = "35",

pages = "1828",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Correction to

T2 - Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era (Leukemia, (2020), 34, 12, (3338-3347), 10.1038/s41375-020-0830-0)

AU - Dhakal, Binod

AU - Patel, Sagar

AU - Girnius, Saulius

AU - Bachegowda, Lohith

AU - Fraser, Raphael

AU - Davila, Omar

AU - Kanate, Abraham S.

AU - Assal, Amer

AU - Hanbali, Amr

AU - Bashey, Asad

AU - Pawarode, Attaphol

AU - Freytes, César O.

AU - Lee, Cindy

AU - Vesole, David

AU - Cornell, Robert Frank

AU - Hildebrandt, Gerhard C.

AU - Murthy, Hemant S.

AU - Lazarus, Hillard M.

AU - Cerny, Jan

AU - Yared, Jean A.

AU - Schriber, Jeffrey

AU - Berdeja, Jesus

AU - Stockerl-Goldstein, Keith

AU - Meehan, Kenneth

AU - Holmberg, Leona

AU - Solh, Melhem

AU - Diaz, Miguel Angel

AU - Kharfan-Dabaja, Mohamed A.

AU - Farhadfar, Nosha

AU - Bashir, Qaiser

AU - Munker, Reinhold

AU - Olsson, Richard F.

AU - Gale, Robert P.

AU - Bayer, Ruthlee Lu

AU - Seo, Sachiko

AU - Chhabra, Saurabh

AU - Hashmi, Shahrukh

AU - Badawy, Sherif M.

AU - Nishihori, Taiga

AU - Gonsalves, Wilson

AU - Nieto, Yago

AU - Efebera, Yvonne

AU - Kumar, Shaji

AU - Shah, Nina

AU - Qazilbash, Muzaffar

AU - Hari, Parameswaran

AU - D’Souza, Anita

PY - 2021/6

Y1 - 2021/6

N2 - The acknowledgement of the original article was incomplete. Correct is should read: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); U24HL138660 from NHLBI and NCI; U24CA233032 from the NCI; OT3HL147741, and U01HL128568 from the NHLBI; HHSH250201700006C, and HHSH250201700007C from the Health Resources and Services Administration (HRSA); and N00014-20-1- 2705 and N00014-20-1-2832 from the Office of Naval Research; Additional federal support is provided by P01CA111412, R01CA152108, R01CA215134, R01C A218285, R01CA231141, R01AI128775, R01HL126589, R01HL129472, R01HL130388, R01HL131731, U01AI 069197, U01AI126612, UG1HL06924, and BARDA. Support is also provided by Be the Match Foundation, Boston Children’s Hospital, Dana Farber, St. Baldrick’s Foundation, Stanford University, the Medical College of Wisconsin the National Marrow Donor Program, and from the following commercial entities: Actinium Pharmaceuticals, Inc.; Adienne SA; Allovir, Inc.; Amgen, Inc.; Angiocrine Bioscience; Astellas Pharma US; bluebird bio, Inc.; Bristol Myers Squibb Co.; Celgene Corp.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd.; Genentech Inc; Incyte Corporation; Janssen/Johnson & Johnson; Jazz Pharmaceuticals, Inc.; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Merck Sharp & Dohme Corp.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Stemcyte; Takeda Pharma; Vor Biopharma; Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. The original article has been corrected.

AB - The acknowledgement of the original article was incomplete. Correct is should read: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); U24HL138660 from NHLBI and NCI; U24CA233032 from the NCI; OT3HL147741, and U01HL128568 from the NHLBI; HHSH250201700006C, and HHSH250201700007C from the Health Resources and Services Administration (HRSA); and N00014-20-1- 2705 and N00014-20-1-2832 from the Office of Naval Research; Additional federal support is provided by P01CA111412, R01CA152108, R01CA215134, R01C A218285, R01CA231141, R01AI128775, R01HL126589, R01HL129472, R01HL130388, R01HL131731, U01AI 069197, U01AI126612, UG1HL06924, and BARDA. Support is also provided by Be the Match Foundation, Boston Children’s Hospital, Dana Farber, St. Baldrick’s Foundation, Stanford University, the Medical College of Wisconsin the National Marrow Donor Program, and from the following commercial entities: Actinium Pharmaceuticals, Inc.; Adienne SA; Allovir, Inc.; Amgen, Inc.; Angiocrine Bioscience; Astellas Pharma US; bluebird bio, Inc.; Bristol Myers Squibb Co.; Celgene Corp.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd.; Genentech Inc; Incyte Corporation; Janssen/Johnson & Johnson; Jazz Pharmaceuticals, Inc.; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Merck Sharp & Dohme Corp.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Stemcyte; Takeda Pharma; Vor Biopharma; Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85103400893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103400893&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01233-1

DO - 10.1038/s41375-021-01233-1

M3 - Comment/debate

C2 - 33782538

AN - SCOPUS:85103400893

SN - 0887-6924

VL - 35

SP - 1828

JO - Leukemia

JF - Leukemia

IS - 6

ER -

Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era (Leukemia, (2020), 34, 12, (3338-3347), 10.1038/s41375-020-0830-0)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this